Navigation Links
Sunpeaks Ventures Enters $45 Billion Specialty Drug Distribution Sector

SILVER SPRING, Md., March 6, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") is pleased to provide this corporate update detailing the Company's business strategy.

Sunpeaks Ventures, through the recent acquisition of its wholly owned subsidiary Healthcare Distribution Specialists ("HDS"), has entered the specialty drug distribution sector.  The U.S. pharmaceutical distribution sector is approximately a $300 billion dollar marketplace.  Within this industry, the three largest drug wholesalers distribute more than 85% of all prescription medication in the United States.  The remaining 15% represents a $45 billion distribution market for specialty pharmaceuticals.  HDS's strategic goal is to become a significant player in this highly fractured secondary wholesale market.

"The hard-to-find and specialty drug sector is rapidly growing and HDS is positioned to become a potential leader in the secondary wholesale market," stated Mr. Mackie Barch, President and CEO of Sunpeaks Ventures.  "With the addition of a veteran sales team, led by Matthew Swift, HDS has the industry experience and know how to gain market share quickly.   If HDS only captures 0.1% of the market, we are looking at potential revenue in excess $45 million from the pharmaceutical distribution business alone.  Based on the performance of Mr. Swift's teams in the past, we believe that we can do significantly better than that given our diversified business and investments in high-tech IT infrastructure.   The opportunity that lies ahead of us is enormous."

In addition to the distribution business, the Company also owns and markets Clotamin®, the world's first specialized over-the-counter multivitamin product designed exclusively for use by patients on Warfarin® or other blood thinners.  The wellbeing and lifestyle of patients prescribed these popular drugs are often compromised by their long list of known adverse drug and food interactions.  Clotamin has been specifically developed and formulated to control and reduce these adverse interactions.  There are over 32 million prescriptions written each year for Warfarin, which equates to millions of potential Clotamin users in the U.S. alone.

Mr. Barch went on to state, "Both myself and other members of my family have been affected by blood clots and have taken blood thinner medications, so our first hand experience has been a major driver in getting Clotamin to market.  Warfarin is one of the most commonly prescribed medications in the world and the people using it do not have many options to supplement their already heavily restricted diet.  We see an enormous market opportunity for Clotamin and other engineered OTC drugs that focus on various specific disease states.  With only modest market penetration rate, we could realize significant revenue and profits."

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market.   HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit

Contact: Financial Insights 888-248-8491 or

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements.  These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.  The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission.  All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement.  Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunpeaks Ventures Completes Acquisition of Healthcare Distribution Specialists LLC
2. 7 Health Ventures Invests in Tulip Medical
3. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
4. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
5. Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC
6. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
7. iPierian Closes $22 Million Series B Financing Led By Google Ventures
8. BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff
9. Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures
10. JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
11. SI-BONE, Inc. Closes $11.0 Million Financing Led by Skyline Ventures
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):